#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14020	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2129	647.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1454	1454	C	793	C	782	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25864	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3767	680.9	0	.	n	.	0	T695C	SNP	695	695	T	1187	1187	C	776	C	759	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25864	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3767	680.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1829	1829	A	794	A,G	778,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25864	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3767	680.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2463	2463	C	819	C,T	793,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25864	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3767	680.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3089	3089	T	818	T,C,A	787,12,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25864	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3767	680.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2537	2537	A	818	A	802	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1836	folP	852	852	100.0	folP.l15.c4.ctg.1	1618	112.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1019	1021	AGC	161;163;165	A,G;G;C	159,1;163;162	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4984	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	139.8	1	SNP	p	S91F	0	.	.	271	273	TCC	603	605	TCC	173;171;170	T;C,T,A;C	167;162,2,1;164	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4984	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	139.8	1	SNP	p	D95G	0	.	.	283	285	GAC	615	617	GAC	163;163;163	G,A;A,G;C,A	158,1;157,1;159,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4984	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	139.8	1	SNP	p	D95N	0	.	.	283	285	GAC	615	617	GAC	163;163;163	G,A;A,G;C,A	158,1;157,1;159,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1499	97.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	500	502	ACC	154;156;150	A,C;C;C	140,2;150;145	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1499	97.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	515	517	CAC	145;147;149	C;A;C	143;143;145	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1499	97.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	698	700	CAC	159;159;159	C,T;A;C	155,2;149;153	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1499	97.3	1	SNP	p	G45D	0	.	.	133	135	GGC	518	520	GGC	151;150;151	G;G;C	147;147;149	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	896	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1068	83.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4598	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3140	144.6	1	SNP	p	D86N	0	.	.	256	258	GAC	589	591	GAC	174;174;174	G;A;C,T	167;170;166,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4598	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3140	144.6	1	SNP	p	S87W	0	.	.	259	261	AGT	592	594	AGT	172;171;172	A;G;T	165;167;164	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4598	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3140	144.6	1	SNP	p	S87I	0	.	.	259	261	AGT	592	594	AGT	172;171;172	A;G;T	165;167;164	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4598	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3140	144.6	1	SNP	p	S87R	0	.	.	259	261	AGT	592	594	AGT	172;171;172	A;G;T	165;167;164	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4598	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3140	144.6	1	SNP	p	S88P	0	.	.	262	264	TCC	595	597	TCC	172;173;175	T;C;C,A	165;164;168,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3954	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2782	140.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1649	1651	GGC	217;215;215	G;G;C	214;212;210	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1268	1270	GCA	195;192;192	G;C;A	194;185;190	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1271	1273	ATC	192;191;189	A;T;C	190;186;184	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1283	1285	GTG	176;176;181	G;T;G	173;169;179	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1283	1285	GTG	176;176;181	G;T;G	173;169;179	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1787	1789	ACC	151;153;152	A,G,C;C;C,T,G	141,2,1;151;145,1,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1841	1843	GCG	131;129;129	G,A;C,G;G	126,1;123,2;126	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1841	1843	GCG	131;129;129	G,A;C,G;G	126,1;123,2;126	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1964	1966	GGC	119;116;115	G,T;G,T;C,T	116,1;113,1;110,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1973	1975	GGC	109;109;109	G,A;G;C	105,1;105;107	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3444	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2452	138.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1991	1993	CCG	72;74;74	C,G;CG,CGG;G	61,1;52,1;60	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5376	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3172	167.4	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1661	1663	CTG	177;177;174	C;T,C;G	163;161,3;162	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2292	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1866	120.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	496	496	C	165	C	155	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	240	porB1a	984	88	96.59	porB1a.l6.c30.ctg.1	419	13.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	69	71	ACG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	437	439	GGA	211;210;212	G;G,A;A	207;203,4;208	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	698	700	CTT	191;195;196	C,T,G;T,C;T,G	183,3,1;185,1;193,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	722	724	GGA	184;182;180	G,A,C;G,A;A	176,3,1;178,1;174	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	806	808	GGT	194;194;195	G;G,A;T	185;183,4;179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	860	862	AGC	211;211;209	A,G;G;C	204,5;208;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	926	926	T	213	T	205	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	1	SNP	p	G120K	0	.	.	358	360	GGT	653	655	GGT	199;196;197	G;G;T,C	193;193;187,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	1	SNP	p	A121N	0	.	.	361	363	GCC	656	658	GCC	197;197;200	G;C;C	194;194;196	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2630	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1561	166.4	1	SNP	p	A121D	0	.	.	361	363	GCC	656	658	GCC	197;197;200	G;C;C	194;194;196	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9224	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5010	182.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2147	2149	AAT	194;194;194	A,C;A;T	186,4;191;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1020	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1120	89.3	1	SNP	p	V57M	1	.	.	169	171	ATG	529	531	ATG	201;203;204	A;T;G	196;195;195	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
